Interleukin 17-producing T helper cells in alloimmunity

Transplantation Reviews

Volumn 23, Issue 1, 2009, Pages 11-18

  Benghiat, Fleur Samantha ^a   Charbonnier, Louis Marie ^a   Vokaer, Benoit ^a   Wilde, Virginie De ^a   Moine, Alain Le ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ALLOIMMUNITY; ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; GRAFT REJECTION; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; REGULATORY T LYMPHOCYTE; RISK FACTOR; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 56249113321     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2008.08.007     Document Type: Article

References (95)

1. Lechler R.I., Garden O.A., and Turka L.A. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 3 (2003) 147-158
2. Goldman M., Le Moine A., Braun M., et al. A role for eosinophils in transplant rejection. Trends Immunol 22 (2001) 247-251
3. Le Moine A., Goldman M., and Abramowicz D. Multiple pathways to allograft rejection. Transplantation 73 (2002) 1373-1381
4. Nickerson P., Steurer W., Steiger J., et al. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 6 (1994) 757-764
5. Le Moine A., and Goldman M. Non-classical pathways of cell-mediated allograft rejection: new challenges for tolerance induction?. Am J Transplant 3 (2003) 101-106
6. Chan S.Y., DeBruyne L.A., Goodman R.E., et al. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 59 (1995) 1155-1161
7. Matesic D., Valujskikh A., Pearlman E., et al. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells. J Immunol 161 (1998) 5236-5244
8. Zelenika D., Adams E., Mellor A., et al. Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. J Immunol 161 (1998) 1868-1874
9. Surquin M., Le Moine A., Flamand V., et al. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates. J Immunol 169 (2002) 500-506
10. Surquin M., Le Moine A., Flamand V., et al. IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts. Transplantation 80 (2005) 1485-1492
11. Piccotti J.R., Chan S.Y., Goodman R.E., et al. IL-12 antagonism induces T helper 2 responses, yet exacerbates cardiac allograft rejection. Evidence against a dominant protective role for T helper 2 cytokines in alloimmunity. J Immunol 157 (1996) 1951-1957
12. Goriely S., Neurath M.F., and Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 8 (2008) 81-86
13. Guillonneau C., Hill M., Hubert F.X., et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117 (2007) 1096-1106
14. Konieczny B.T., Dai Z., Elwood E.T., et al. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 160 (1998) 2059-2064
15. Markees T.G., Phillips N.E., Gordon E.J., et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 101 (1998) 2446-2455
16. Sawitzki B., Kingsley C.I., Oliveira V., et al. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 201 (2005) 1925-1935
17. Thebault P., Condamine T., Heslan M., et al. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 7 (2007) 2472-2482
18. Wood K.J., Feng G., Wei B., et al. Interferon gamma: friend or foe?. Transplantation 84 (2007) S4-S5
19. Long E., and Wood K.J. Understanding FOXP3: progress towards achieving transplantation tolerance. Transplantation 84 (2007) 459-461
20. Roncarolo M.G., and Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7 (2007) 585-598
21. Kang S.M., Tang Q., and Bluestone J.A. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 7 (2007) 1457-1463
22. Deaglio S., Dwyer K.M., Gao W., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 (2007) 1257-1265
23. Gavin M.A., Rasmussen J.P., Fontenot J.D., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
24. Tang Q., and Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9 (2008) 239-244
25. Collison L.W., Workman C.J., Kuo T.T., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007) 566-569
26. Chen L., Wang T., Zhou P., et al. TLR engagement prevents transplantation tolerance. Am J Transplant 6 (2006) 2282-2291
27. Schenk S., Kish D.D., He C., et al. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol 174 (2005) 3741-3748
28. Benghiat F.S., Graca L., Braun M.Y., et al. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 79 (2005) 648-654
29. Graca L., Le Moine A., Cobbold S.P., et al. Dominant transplantation tolerance. Opinion. Curr Opin Immunol 15 (2003) 499-506
30. Yang J., Brook M.O., Carvalho-Gaspar M., et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A 104 (2007) 19954-19959
31. Suryani S., and Sutton I. An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol 183 (2007) 96-103
32. Annunziato F., Cosmi L., Santarlasci V., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 204 (2007) 1849-1861
33. Acosta-Rodriguez E.V., Rivino L., Geginat J., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8 (2007) 639-646
34. Ferretti S., Bonneau O., Dubois G.R., et al. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170 (2003) 2106-2112
35. Lockhart E., Green A.M., and Flynn J.L. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177 (2006) 4662-4669
36. Michel M.L., Keller A.C., Paget C., et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204 (2007) 995-1001
37. Molet S., Hamid Q., Davoine F., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 108 (2001) 430-438
38. Stark M.A., Huo Y., Burcin T.L., et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 22 (2005) 285-294
39. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
40. Liu X.K., Lin X., and Gaffen S.L. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem 279 (2004) 52762-52771
41. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
42. Veldhoen M., Hocking R.J., Atkins C.J., et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
43. Alegre M.L., Florquin S., and Goldman M. Cellular mechanisms underlying acute graft rejection: time for reassessment. Curr Opin Immunol 19 (2007) 563-568
44. Goriely S., and Goldman M. The IL-12 family: new players in transplantation immunity. Am J Transplant 7 (2007) 278-284
45. Goldstein D.R., Tesar B.M., Palmer S.M., et al. Toll-like receptors and allograft rejection. Am J Respir Crit Care Med 169 (2004) 971-972
46. Nurieva R., Yang X.O., Martinez G., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448 (2007) 480-483
47. Sundrud M.S., and Rao A. Regulation of T helper 17 differentiation by orphan nuclear receptors: it's not just ROR gamma t anymore. Immunity 28 (2008) 5-7
48. Yang X.O., Pappu B.P., Nurieva R., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28 (2008) 29-39
49. Weaver C.T., Harrington L.E., Mangan P.R., et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
50. Chen Z., Laurence A., and O'Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 19 (2007) 400-408
51. Goriely S., and Goldman M. Interleukin-12 family members and the balance between rejection and tolerance. Curr Opin Organ Transpl 13 (2008) 4-9
52. Chen Y., Langrish C.L., McKenzie B., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116 (2006) 1317-1326
53. Murphy C.A., Langrish C.L., Chen Y., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198 (2003) 1951-1957
54. Cua D.J., Sherlock J., Chen Y., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003) 744-748
55. Pflanz S., Timans J.C., Cheung J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16 (2002) 779-790
56. Stumhofer J.S., Laurence A., Wilson E.H., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7 (2006) 937-945
57. Batten M., Li J., Yi S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 7 (2006) 929-936
58. Stumhofer J.S., Silver J.S., Laurence A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8 (2007) 1363-1371
59. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007) 139-145
60. Lohr J., Knoechel B., Wang J.J., et al. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 203 (2006) 2785-2791
61. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 178 (2007) 6725-6729
62. Korn T., Bettelli E., Gao W., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 (2007) 484-487
63. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 (2007) 950-957
64. Sutton C., Brereton C., Keogh B., et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203 (2006) 1685-1691
65. Amadi-Obi A., Yu C.R., Liu X., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13 (2007) 711-718
66. Singh S.P., Zhang H.H., Foley J.F., et al. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180 (2008) 214-221
67. Lim H.W., Lee J., Hillsamer P., et al. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 180 (2008) 122-129
68. Hirota K., Yoshitomi H., Hashimoto M., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204 (2007) 2803-2812
69. Aujla S.J., Chan Y.R., Zheng M., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14 (2008) 275-281
70. Afzali B., Lombardi G., Lechler R.I., et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148 (2007) 32-46
71. Fujino S., Andoh A., Bamba S., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
72. Nakae S., Nambu A., Sudo K., et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171 (2003) 6173-6177
73. Ogawa A., Andoh A., Araki Y., et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 110 (2004) 55-62
74. Hsu H.C., Yang P., Wang J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 9 (2008) 166-175
75. Antonysamy M.A., Fanslow W.C., Fu F., et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 162 (1999) 577-584
76. Antonysamy M.A., Fanslow W.C., Fu F., et al. Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc 31 (1999) 93
77. Chen Y., and Wood K.J. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection. Transplantation 84 (2007) 1071-1074
78. Tang J.L., Subbotin V.M., Antonysamy M.A., et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 72 (2001) 348-350
79. Loong C.C., Lin C.Y., and Lui W.Y. Expression of interleukin-17 as a predictive parameter in acute renal allograft rejection. Transplant Proc 32 (2000) 1773
80. Loong C.C., Hsieh H.G., Lui W.Y., et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 197 (2002) 322-332
81. Van Kooten C., Boonstra J.G., Paape M.E., et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 9 (1998) 1526-1534
82. Vanaudenaerde B.M., Dupont L.J., Wuyts W.A., et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 27 (2006) 779-787
83. Burlingham W.J., Love R.B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 117 (2007) 3498-3506
84. Yoshida S., Haque A., Mizobuchi T., et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 6 (2006) 724-735
85. Vanaudenaerde B.M., Wuyts W.A., Geudens N., et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 7 (2007) 76-82
86. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174 (2006) 566-570
87. Healy D.G., Watson R.W., O'Keane C., et al. Neutrophil transendothelial migration potential predicts rejection severity in human cardiac transplantation. Eur J Cardiothorac Surg 29 (2006) 760-766
88. Miura M., El Sawy T., and Fairchild R.L. Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma. Am J Pathol 162 (2003) 509-519
89. Benghiat F.S., Craciun L., De Wilde V., et al. IL-17 production elicited by allo-MHC class II recognition depends on CD25+CD4+ T cells. Transplantation 85 (2008) 943-949
90. Xia G., He J., Zhang Z., et al. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation 82 (2006) 1749-1755
91. Liao J.J., Huang M.C., and Goetzl E.J. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 178 (2007) 5425-5428
92. Kauffman C.L., Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123 (2004) 1037-1044
93. Toichi E., Torres G., McCormick T.S., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 177 (2006) 4917-4926
94. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167
95. Smolen J.S., and Maini R.N. Interleukin-6: a new therapeutic target. Arthritis Res Ther 8 Suppl 2 (2006) S5